MapLight Therapeutics, Inc. (MPLT)
NASDAQ:MPLT
Want to see MPLT full AI Analyst Report?
MPLT Stock Chart & Stats
$17.49
--
Market closed
$17.49
--
Day’s Range― - ―
52-Week Range$12.24 - $33.28
Previous CloseN/A
VolumeN/A
Average Volume (3M)401.63K
Market Cap
$1.18B
Enterprise Value-$27.42M
Total Cash (Recent Filing)$310.11M
Total Debt (Recent Filing)$5.59M
Price to Earnings (P/E)―
Beta1.62
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding42,610,080
10 Day Avg. Volume205,334
30 Day Avg. Volume401,626
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.69
Price to Sales (P/S)0.00
P/FCF Ratio-5.58
Enterprise Value/Market Cap-0.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit47.77
Enterprise Value/Ebitda0.13
Forecast
1Y Price Target
$39.05Price Target Upside123.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Sizable EquityA very low debt-to-equity ratio and substantial equity provide durable financial flexibility for a clinical-stage biotech. This capital base supports ongoing trials, enables partner discussions and reduces near-term default risk, giving management runway to execute development plans without immediate forced financing.
Expanding CNS Pipeline With Fast TrackA diversified set of CNS programs across schizophrenia, autism and Alzheimer’s psychosis plus an FDA Fast Track designation create structural R&D value. Multiple mid-stage trials reduce single-program binary risk and the Fast Track status can accelerate development and regulatory interactions, improving long-term commercialization odds.
Orderly Board Refresh Strengthens GovernancePlanned board changes that add industry-experienced directors while maintaining continuity improve oversight during a pivotal clinical period. Strengthened governance can enhance strategic decision-making, execution of clinical programs and credibility with investors and partners over the medium term.
Bears Say
Accelerating Operating Cash BurnRapidly rising negative operating cash flow materially shortens the time before additional funding is needed. Higher burn increases dilution or financing risk, constrains strategic optionality and can force budget cuts or delayed programs if trial results or capital markets weaken, pressuring long-term execution.
Pre-revenue With Widening Net LossesBeing pre-revenue with materially wider annual losses means the company cannot self-fund development through sales. Sustained negative returns on equity increase reliance on capital markets and make long-term viability contingent on successful clinical readouts and subsequent commercialization or partnerships.
Rising R&D And G&A Tied To TrialsSurging R&D and G&A reflect higher trial activity but also raise the fixed-cost base. This magnifies funding needs and makes the company's outlook highly sensitive to trial timelines and outcomes; failed or delayed readouts would worsen cash strain and limit strategic flexibility over months to years.
MapLight Therapeutics, Inc. News
MPLT FAQ
What was MapLight Therapeutics, Inc.’s price range in the past 12 months?
MapLight Therapeutics, Inc. lowest stock price was $12.24 and its highest was $33.28 in the past 12 months.
What is MapLight Therapeutics, Inc.’s market cap?
MapLight Therapeutics, Inc.’s market cap is $1.18B.
When is MapLight Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were MapLight Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is MapLight Therapeutics, Inc. overvalued?
According to Wall Street analysts MapLight Therapeutics, Inc.’s price is currently Undervalued.
Does MapLight Therapeutics, Inc. pay dividends?
MapLight Therapeutics, Inc. does not currently pay dividends.
What is MapLight Therapeutics, Inc.’s EPS estimate?
MapLight Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MapLight Therapeutics, Inc. have?
MapLight Therapeutics, Inc. has 42,610,080 shares outstanding.
What happened to MapLight Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MapLight Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MPLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MapLight Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.05 (123.26% Upside)
$39.05 (123.26% Upside)
Insider Transactions
Sold Shares
Worth $623.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-69.06%
Trailing 12-Months
Asset Growth
275.37%
Trailing 12-Months
Company Description
MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. MapLight Therapeutics, Inc. was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California. MapLight Therapeutics, Inc operates as a subsidiary of Catalyst4, Inc.
MPLT Stock 12 Month Forecast
Average Price Target
$39.05
▲(123.26% Upside)
Scinai Immunotherapeutics
―
Sensei Biotherapeutics
―
GRI Bio
―
Dermata Therapeutics
―
Azitra Inc
―
Ownership Overview
63.47% Insiders
6.26% Mutual Funds
10.50% Other Institutional Investors
15.68% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---